NYSEMKT: YCBD
Cbdmd Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their YCBD stock forecasts and price targets.

Forecast return on equity

Is YCBD forecast to generate an efficient return?

Company
-8.32%
Industry
35.2%
Market
149.97%
YCBD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is YCBD forecast to generate an efficient return on assets?

Company
-6.36%
Industry
15.05%
YCBD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

YCBD earnings per share forecast

What is YCBD's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.14
Avg 2 year Forecast
-$0.07

YCBD revenue forecast

What is YCBD's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$21.6M+13.27%
Avg 2 year Forecast
$23.1M+21.2%
YCBD's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

YCBD revenue growth forecast

How is YCBD forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
13.27%
Industry
9.18%
Market
26.17%
YCBD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
YCBD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

YCBD vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
YCBD$0.72N/AN/A
BGM$0.93N/AN/A
GELS$0.80N/AN/A
QNTM$2.36N/AN/A
SBFM$1.11$7.00+530.63%Strong Buy

Cbdmd Stock Forecast FAQ

What is YCBD's earnings growth forecast for 2026-2027?

(NYSEMKT: YCBD) Cbdmd's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 45.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,660.37%.

Cbdmd's earnings in 2026 is -$3,714,599.On average, 3 Wall Street analysts forecast YCBD's earnings for 2026 to be -$1,498,766, with the lowest YCBD earnings forecast at -$1,439,991, and the highest YCBD earnings forecast at -$1,542,847.

In 2027, YCBD is forecast to generate -$749,383 in earnings, with the lowest earnings forecast at -$719,995 and the highest earnings forecast at -$771,424.

If you're new to stock investing, here's how to buy Cbdmd stock.

What is YCBD's revenue growth forecast for 2026-2027?

(NYSEMKT: YCBD) Cbdmd's forecast annual revenue growth rate of 13.27% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.17%.

Cbdmd's revenue in 2026 is $19,093,896.On average, 3 Wall Street analysts forecast YCBD's revenue for 2026 to be $226,987,498, with the lowest YCBD revenue forecast at $218,087,262, and the highest YCBD revenue forecast at $233,662,675.

In 2027, YCBD is forecast to generate $242,877,777 in revenue, with the lowest revenue forecast at $233,347,808 and the highest revenue forecast at $250,014,759.

What is YCBD's forecast return on assets (ROA) for 2026-2027?

(NYSEMKT: YCBD) forecast ROA is -6.36%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 15.05%.

What is YCBD's Earnings Per Share (EPS) forecast for 2026-2027?

(NYSEMKT: YCBD) Cbdmd's current Earnings Per Share (EPS) is -$1.68. On average, analysts forecast that YCBD's EPS will be -$0.14 for 2026, with the lowest EPS forecast at -$0.14, and the highest EPS forecast at -$0.15. In 2027, YCBD's EPS is forecast to hit -$0.07 (min: -$0.07, max: -$0.07).

What is YCBD's forecast return on equity (ROE) for 2026-2027?

(NYSEMKT: YCBD) forecast ROE is -8.32%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.